⚠️ System Notice: The registration module is now online. Wire transfer payments in the ordering module are now active. Credit card payment implementation will continue until 20.04.2026.
Shopping Cart
CATEGORIES

Anti-BrdU Monoclonal Antibody

Product classification
Antibodies Loading Control Antibodies
Catalog No CAB.15464
Antibody overview
CAB.15464 Antibodies
Anti-BrdU Monoclonal Antibody
Ordering
Available Variants
2 Variants
Change View
50ul
SKU
CAB.15464-50ul
Price
€562.50
Available – Dispatch in 14 days
100ul
SKU
CAB.15464-100ul
Price
€1022.50
Available – Dispatch in 14 days
Availability & Stock Pack SKU Price (EUR)
Available – Dispatch in 14 days
Global Network - International delivery
50ul CAB.15464-50ul €562.50
Available – Dispatch in 14 days
Global Network - International delivery
100ul CAB.15464-100ul €1022.50
Quick page guide: Compare pack sizes, review validated applications and access product documents from this section.
Recommended Dilution
IF/ICC 1:50-200
Validated Application Key
ELISA
Validated application
ELISA - Enzyme-Linked Immunosorbent Assay
IF
Validated application
IF - Validated application
ICC
Validated application
ICC - Validated application
Technical Specifications
Catalog No CAB.15464
Product Name Anti-BrdU Monoclonal Antibody
Isotype IgG
Calculated MW N/A
Immunogen Bromodeoxyuridine
Public Immunogen Range N/A
Host Mouse
Clone Type Monoclonal Antibody
Reactivity ALL
Application ELISA;IF/ICC
Subcellular Location N/A
Purification Method CABfinity purification
Storage Buffer PBS with 0.02% sodium azide,50% glycerol,pH7.3.
Storage Store at -20℃. Avoid freeze/thaw cycles.

Background

Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU, BUdR, BrdUrd) is a synthetic nucleoside that is an analog of thymidine. It can be incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication. As such, BrdU is used for birth dating and monitoring cell proliferation. BrdU is a toxic and mutagenic substance. It triggers cell death, the formation of teratomas, alters DNA stability, lengthens the cell cycle, and has mitogenic, transcriptional and translational effects on cells that incorporate it.

Protocol / Instructions

Recommended workflow
Optimized handling and experimental guidance
Review the suggested sequence below before starting the assay to keep sample handling, incubation, and downstream interpretation aligned.
Lab-ready steps

The Anti-BrdU Monoclonal Antibody is a valuable tool for detecting bromodeoxyuridine (BrdU) incorporation in various applications. Below are the protocols for the validated applications.

## ELISA Protocol

For ELISA, the Anti-BrdU Monoclonal Antibody can be used to detect BrdU incorporation in DNA. Reagents or buffers required include the antibody, BrdU-labeled DNA, and an ELISA plate. Sample preparation involves coating the ELISA plate with BrdU-labeled DNA. Antibody incubation is performed by adding the Anti-BrdU Monoclonal Antibody at the recommended dilution. Washing and detection are carried out according to standard ELISA protocols. Technical notes: Ensure proper blocking and washing steps to minimize non-specific binding.

## IF/ICC Protocol

For Immunofluorescence (IF) or Immunocytochemistry (ICC), the Anti-BrdU Monoclonal Antibody is used to detect BrdU incorporation in cells. Reagents or buffers required include the antibody, a fluorescent secondary antibody, and a mounting medium. Sample preparation involves fixing and permeabilizing cells, followed by denaturation of DNA to expose the BrdU epitope. Antibody incubation is performed by adding the Anti-BrdU Monoclonal Antibody at the recommended dilution. Washing and detection are carried out using a fluorescent secondary antibody. Technical notes: Optimize the denaturation step to achieve the best signal-to-noise ratio.

Precautions

Store at 2-8°C. Handle with care, and avoid freeze-thaw cycles. Use appropriate controls and optimize antibody dilution for each application.

Validation Images

Anti-BrdU Monoclonal Antibody Figure 1
Fig.1. Validation data.